[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20170356A - Composiciones farmacéuticas para terapia combinada - Google Patents

Composiciones farmacéuticas para terapia combinada

Info

Publication number
CR20170356A
CR20170356A CR20170356A CR20170356A CR20170356A CR 20170356 A CR20170356 A CR 20170356A CR 20170356 A CR20170356 A CR 20170356A CR 20170356 A CR20170356 A CR 20170356A CR 20170356 A CR20170356 A CR 20170356A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
combined therapy
agonist
ppar
delta
Prior art date
Application number
CR20170356A
Other languages
English (en)
Inventor
Luciano Adorini
Mark Pruzanski
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170356(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CR20170356A publication Critical patent/CR20170356A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende una combinación de un agonista de FXR y por lo menos un agente reductor de lípidos (por ejemplo, un agonista de PPAR-alfa, agonista de PPAR-delta, agonista dual de PPAR-alfa y delta, y/o estatina)
CR20170356A 2015-02-06 2016-02-05 Composiciones farmacéuticas para terapia combinada CR20170356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (en) 2015-02-06 2016-02-05 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
CR20170356A true CR20170356A (es) 2018-02-28

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170356A CR20170356A (es) 2015-02-06 2016-02-05 Composiciones farmacéuticas para terapia combinada

Country Status (31)

Country Link
US (3) US11311557B2 (es)
EP (2) EP4035665A1 (es)
JP (2) JP7306791B2 (es)
KR (1) KR20170115071A (es)
CN (1) CN107405325B (es)
AR (1) AR103624A1 (es)
AU (2) AU2016215179B2 (es)
BR (1) BR112017016766B1 (es)
CA (1) CA2976056C (es)
CL (3) CL2017001983A1 (es)
CO (1) CO2017007959A2 (es)
CR (1) CR20170356A (es)
DK (1) DK3253382T3 (es)
EA (1) EA036404B1 (es)
EC (1) ECSP17057848A (es)
ES (1) ES2905872T3 (es)
GT (1) GT201700174A (es)
HK (1) HK1246191A1 (es)
IL (2) IL253719B (es)
MA (1) MA40814A1 (es)
MX (1) MX2017010131A (es)
NI (1) NI201700100A (es)
PE (1) PE20180027A1 (es)
PH (1) PH12017501384A1 (es)
SG (1) SG11201706347SA (es)
SV (1) SV2017005512A (es)
TN (1) TN2017000344A1 (es)
TW (1) TW201628625A (es)
UA (1) UA125744C2 (es)
WO (1) WO2016127019A2 (es)
ZA (1) ZA201706007B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706347SA (en) 2015-02-06 2017-09-28 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
JP6879931B2 (ja) * 2015-04-07 2021-06-02 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法用の医薬組成物
MX2018003649A (es) * 2015-09-24 2018-05-11 Intercept Pharmaceuticals Inc Metodos e intermedios para la preparacion de derivados de acido biliar.
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
MX2021015783A (es) * 2016-03-31 2022-12-09 Genfit Metodos de tratamiento de enfermedades colestaticas.
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
ES2894261T3 (es) * 2016-12-09 2022-02-14 Cadila Healthcare Ltd Tratamiento de la colangitis biliar primaria
CA3051776A1 (en) * 2017-02-21 2018-08-30 Genfit Combination of a ppar and fxr agonist for the treatment of liver disorders
US20190076500A1 (en) * 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2022528549A (ja) * 2019-04-10 2022-06-14 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
JP2022536060A (ja) * 2019-05-30 2022-08-12 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
CA3139291A1 (en) * 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
JP2022548725A (ja) * 2019-09-20 2022-11-21 レネオ ファーマシューティカルズ，インク． 腎臓病の治療におけるｐｐａｒデルタアゴニストの使用
US20220387467A1 (en) * 2019-11-22 2022-12-08 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2024132001A1 (en) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (es) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI52570C (fi) 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (es) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (es) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ES2156120T3 (es) 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2001509165A (ja) 1997-01-24 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バリヤ機能の回復、表皮の分化の促進及び増殖の抑制のためのＦＸＲ、ＰＰＡＲα及びＬＸＲαの活性剤の使用
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
BR9812772A (pt) 1997-10-27 2000-10-10 Reddy Research Foundation "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos"
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
EP1140036A2 (en) 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
CA2356887A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2001080852A1 (en) 2000-04-19 2001-11-01 Borody Thomas J Compositions and therapies for hyperlipidaemia-associated disorders
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ES2609395T5 (es) 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
CA2679608A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
EA015632B9 (ru) 2006-05-24 2012-08-30 Эли Лилли Энд Компани Агонисты fxr
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
CN101534825A (zh) 2006-08-04 2009-09-16 Aska制药株式会社 含有贝特类药物的制剂及其制备方法
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
LT2641596T (lt) * 2009-11-26 2018-08-10 Genfit 1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui
NZ703072A (en) 2012-06-19 2016-06-24 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
PT2912013T (pt) 2012-10-26 2018-01-03 Intercept Pharmaceuticals Inc Processo de preparação de derivados de ácidos biliares
SI3360881T1 (sl) * 2013-05-14 2021-06-30 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-substituirani derivati žolčnih kislin in aminokislinski konjugati le-teh kot modulatorji receptorja farnezoid X
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
SG11201706347SA (en) 2015-02-06 2017-09-28 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
TW201628625A (zh) 2016-08-16
PH12017501384A1 (en) 2018-01-08
US11311557B2 (en) 2022-04-26
BR112017016766A2 (pt) 2018-04-10
JP7306791B2 (ja) 2023-07-11
SV2017005512A (es) 2018-06-12
MA40814A1 (fr) 2019-08-30
EP3253382A2 (en) 2017-12-13
US20220280534A1 (en) 2022-09-08
EA036404B1 (ru) 2020-11-06
CL2018003604A1 (es) 2019-02-22
US20180008616A1 (en) 2018-01-11
CL2018001006A1 (es) 2018-06-15
US20220280533A1 (en) 2022-09-08
CA2976056A1 (en) 2016-08-11
ECSP17057848A (es) 2017-10-31
EA201791770A1 (ru) 2017-12-29
TN2017000344A1 (en) 2019-01-16
IL290823A (en) 2022-04-01
DK3253382T3 (da) 2022-02-14
ZA201706007B (en) 2019-01-30
JP2022000483A (ja) 2022-01-04
AU2021201015A1 (en) 2021-03-11
EP3253382A4 (en) 2018-10-31
SG11201706347SA (en) 2017-09-28
ES2905872T3 (es) 2022-04-12
EP3253382B1 (en) 2021-11-17
PE20180027A1 (es) 2018-01-09
WO2016127019A3 (en) 2016-11-03
CA2976056C (en) 2024-02-06
KR20170115071A (ko) 2017-10-16
EP4035665A1 (en) 2022-08-03
BR112017016766B1 (pt) 2023-11-07
MX2017010131A (es) 2017-11-01
AR103624A1 (es) 2017-05-24
CN107405325B (zh) 2021-11-12
UA125744C2 (uk) 2022-06-01
WO2016127019A2 (en) 2016-08-11
NI201700100A (es) 2018-09-06
HK1246191A1 (zh) 2018-09-07
CL2017001983A1 (es) 2018-04-20
IL253719B (en) 2022-04-01
AU2016215179B2 (en) 2021-02-25
AU2016215179A1 (en) 2017-08-24
CN107405325A (zh) 2017-11-28
GT201700174A (es) 2018-11-13
JP2018504438A (ja) 2018-02-15
IL253719A0 (en) 2017-09-28
CO2017007959A2 (es) 2017-10-31

Similar Documents

Publication Publication Date Title
CR20170356A (es) Composiciones farmacéuticas para terapia combinada
BR112022003543A2 (pt) Inibidores de kras g12
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
BR112017022089A2 (pt) uso de uma composição, e, método para branqueamento de dentes
UY37113A (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CY1124475T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
NI201400042A (es) 2 - tiopirimidinonas
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
BR112013019394A2 (pt) uso de um agente
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112018012043A2 (pt) processo para a redução da transpiração
UY35823A (es) Profármacos de antagonista de nmda
BR112018001793A2 (pt) preparação cosmética de redução do suor
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
BR112019002120A2 (pt) composição anti-retroviral de várias classes
CR20170498A (es) 2-tiopirimidinonas
BR112018006444A2 (pt) processo para a preparação de uma composição lipossomal unilamelar e composição lipossomal liofilizada
BR112017006613A2 (pt) composição herbicida e processo da mesma
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
UY35294A (es) Composición farmacéutica sólida para administración bucal de agomelatina